Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 10/20 | 0.63 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30281213 | 1.00 | NR4A2 (0.63) | NR4A2MRGPRX4KMT2AAKR1C3NR4A1 | |
| SCHEMBL2714234 | 0.85 | MAOB (0.66) | NR4A2KMT2A | |
| SCHEMBL15036779 | 0.85 | PARP1 (0.56) | NR4A2MRGPRX4KMT2A | |
| SCHEMBL15350562 | 0.84 | KMT2A (0.65) | NR4A2MRGPRX4KMT2AAKR1C3NR4A1 | |
| SCHEMBL25790210 | 0.83 | NR4A2 (0.53) | NR4A2MRGPRX4KMT2AAKR1C3NR4A1 | |
| SCHEMBL28069946 | 0.83 | MRGPRX4 (0.56) | MRGPRX4NPC1RAB9AL3MBTL1 | |
| SCHEMBL27931854 | 0.83 | MAOB (0.49) | NR4A2MRGPRX4KMT2ANPC1RAB9A | |
| SCHEMBL849776 | 0.83 | KMT2A (0.63) | NR4A2MRGPRX4KMT2AAKR1C3NR4A1 | |
| SCHEMBL977465 | 0.82 | MAPT (0.55) | NR4A2MRGPRX4KMT2AL3MBTL1 | |
| SCHEMBL27893393 | 0.82 | L3MBTL1 (0.51) | NR4A2MRGPRX4KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-02 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| CN-115884810-A | Imidazopyridazines as IL-17 modulators | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230081548-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-16 | — | — | US | disclosed |
| EP-4143195-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2022-12-22 | — | — | US | disclosed |
| WO-2021222404-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN BIOTECH, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-2807162-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013161308-A1 | AMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013110590-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | WO | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | US | disclosed |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | US | disclosed |
| EP-1635835-B1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20060293340-A1 | 2-Aminopyrimidine derivatives as raf kinase inhibitors | NOVARTIS AG (CH) | 2006-12-28 | — | — | US | disclosed |
| EP-1635835-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110452-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | NR4A2 231/4885MRGPRX4 102/4885KMT2A 2634/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | NR4A2 231/4885MRGPRX4 102/4885KMT2A 2634/4885 |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | NR4A2 231/4885MRGPRX4 102/4885KMT2A 2634/4885 |
| US-20230081548-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | NR4A2 231/4885MRGPRX4 102/4885KMT2A 2634/4885 |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | NR4A2 2333/4885MRGPRX4 1731/4885KMT2A 1764/4885 |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | NR4A2 231/4885MRGPRX4 102/4885KMT2A 2634/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | NR4A2 231/4885MRGPRX4 102/4885KMT2A 2634/4885 |
| US-20060293340-A1 | 2-Aminopyrimidine derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | NR4A2 999/4885MRGPRX4 2994/4885KMT2A 824/4885 |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | VHL, FLT4, FLT1 | NR4A2 790/4885MRGPRX4 2253/4885KMT2A 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.